XTALPi Partners with Singapore Institutions to Advance AI-Driven Peptide Drug for Clear Cell Renal Cell Carcinoma

　　【Pharmaceutical Network Medical Stock Market】Currently, "AI + pharmaceuticals" is opening up a new track in the biopharmaceuticals industry. Traditional drug development has high thresholds, is time-consuming, and challenging. However, with the support of AI, the success rate of new drug development pipelines will be greatly increased, helping pharmaceutical companies reduce costs. As China's innovative drug development continues to thrive, Chinese AI pharmaceutical enterprises have sprung up like mushrooms after rain, with continuous new developments.
 

Recently, XtalPi announced that it has launched an AI-driven drug discovery collaboration with the National Cancer Centre Singapore (NCCS) and Duke-NUS Medical School. This partnership will utilize XtalPi's AI and automation-powered peptide R&D design platform to discover and design new clinical candidate drugs targeting clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer.
 

ccRCC is a common type in renal cancer cases, with limited treatment options often relying on surgery and traditional chemotherapy. There remains a significant unmet treatment need for patients.
 

XtalPi and NCCS Jointly Conduct Research to Analyze Patient Data Through AI Algorithms, Identify New Receptor Targets That Can Be Precisely Targeted by Innovatively Designed Peptide Drugs, Thereby Enhancing Treatment Efficacy.
 

XtalPi's Agreement with Two Singapore Research Institutions Emphasizes Sharing of Future Commercialization Outcomes, Paving the Way for Future Drug Launches
 

Public information shows that XtalPi Holdings Limited was listed on the Hong Kong Stock Exchange on June 13 this year. XtalPi focuses on AI in the fields of life sciences and new materials.RobotTechnological innovation, mainly providing drug discovery solutions and intelligent automation solutions to the industry. As of now, XtalPi is still in a loss-making state, with an adjusted net loss of approximately RMB 522 million in 2023.
 

The National Cancer Centre Singapore (NCCS) not only has significant advantages in clinical treatment but also makes important contributions in academic research and international cooperation.
 

Duke-NUS Medical School is committed to enhancing medical practice standards in Singapore and globally through innovative education and scientific research.
 

According to reports, Singapore is actively promoting the integration of generative AI models and applications in its healthcare system, with all these projects receiving strong policy support.
 

In October this year, Singapore's Ministry of Health announced an investment of S$200 million (approximately US$150 million) to promote new artificial intelligence technologies across the country’s healthcare system over the next five years. This investment aims to support the development and piloting of technological innovations and drive their large-scale application throughout the system. It was also revealed that a nationwide genomic sequencing initiative will be launched by mid-next year, initially targeting familial hypercholesterolemia. Additionally, the Ministry stated it would enhance national governance for AI use in healthcare to ensure safe and reliable patient care while promoting the development and deployment of more AI solutions.

 

In 2023, Synapxe, the national health technology agency, expanded its collaboration with Microsoft to develop the "Secure GPT" platform, providing healthcare professionals with a public platform for developing large language models and generative AI applications. Meanwhile, the National University System launched NUHSUSSELL-GPT, a chatbot based on large language models that can quickly summarize patient medical records and draft referral letters. Singapore General Hospital is also researching ways to apply generative AI technology in pre-surgical assessments. Additionally, the Ministry of Health is promoting the adoption of medical imaging AI through the national radiology AI platform, AimSG, which was introduced last year. Currently, two hospitals under SingHealth have implemented AI for chest X-ray analysis, and the National Healthcare Group is piloting the technology within its cluster.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.